Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Annual Business Results
May 26, 2003
- 50th Anniversary of DNA Discovery Celebrated
May 26, 2003
- Shoda Appointed President of Sankyo
May 26, 2003
- Annual Business Results
May 26, 2003
- RESEARCH &DEVELOPMENT NEWS IN BRIEF
May 26, 2003
- BULLETIN
May 26, 2003
- Annual Business Results
May 26, 2003
- OTC NEWS IN BRIEF
May 26, 2003
- Tanabe Calls For Sales of \192.0 Billion in New 3-Year Plan
May 26, 2003
- Annual Business Results
May 26, 2003
- MEDICAL DEVICE NEWS IN BRIEF
May 26, 2003
- Kissei Aims to Increase Sales, 1.3 Times by 2008: New Management Plan
May 26, 2003
- Annual Business Results
May 26, 2003
- DIAGNOSTIC NEWS IN BRIEF
May 26, 2003
- Takara Bio to Promote Anti-cancer Immunotherapy via JV
May 26, 2003
- Annual Business Results
May 26, 2003
- WORLD NEWS IN BRIEF
May 26, 2003
- Aventis Appoints "General Manufacturing/Marketing Manager" Ahead of PAL Amendment
May 26, 2003
- Korosho Calls For Healthcare Supply System Reform Centered on Patients
May 26, 2003
- BULLETIN
May 26, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…